HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endometrial pattern in patients with primary hypoestrogenic amenorrhea receiving estrogen replacement therapy.

Abstract
The histologic pattern of the endometrium was studied in 38 patients, 19 to 44 years old, with primary hypoestrogenic amenorrhea treated by estrogen replacement therapy. At the time of endometrial biopsy 3 patients were receiving estrogens only and 35 patients were taking 1 of the following cyclic estrogen-progestogen combinations: 1) conjugated estrogens, 1.25 or 2.5 mg per day, combined with medroxyprogesterone, 5 or 10 mg for the last 5 to 10 days; 2) ethinyl estradiol, 50 microgram per day, combined with medroxyprogesterone, 5 mg per day for the last 5 days; or 3) mestranol, 40 microgram per day, in combination with norethindrone, 0.5 mg for the last 7 days. Evidence of endometrial hyperplasia was found in 3 patients. Two of them were taking unopposed estrogens and developed cystic hyperplasia; the other patient, treated with norethindrone in addition to mestranol, disclosed focal cystic glandular hyperplasia. This study and the review of the available data reported in the literature on the endometrial response to estrogen therapy in patients with gonadal dysgenesis stress the importance of appropriate estrogen and progestogen dosage to avoid the hazards of abnormal endometrial pattern in young patients receiving estrogen replacement therapy.
AuthorsJ Van Campenhout, P Choquette, R Vauclair
JournalObstetrics and gynecology (Obstet Gynecol) Vol. 56 Issue 3 Pg. 349-55 (Sep 1980) ISSN: 0029-7844 [Print] United States
PMID7422173 (Publication Type: Journal Article)
Chemical References
  • Drug Combinations
  • Estrogens
  • Gonadotropins
  • Progestins
Topics
  • Adult
  • Amenorrhea (drug therapy)
  • Biopsy
  • Drug Combinations
  • Drug Therapy, Combination
  • Endometrial Hyperplasia (chemically induced, pathology)
  • Endometrium (pathology)
  • Estrogens (adverse effects, therapeutic use)
  • Female
  • Gonadal Dysgenesis (drug therapy)
  • Gonadotropins (deficiency)
  • Humans
  • Ovarian Diseases (drug therapy)
  • Progestins (adverse effects, therapeutic use)
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: